Magenta Therapeutics Inc MGTA:NASDAQ

Last Price$3.57NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$3.50 (1)
Ask (Size)$3.58 (6)
Day Low / HighN/A - N/A
Volume249.4 K
 

View Biotechnology IndustryPeer Comparison as of 01/21/2022

 

Magenta Therapeutics Inc ( NASDAQ )

Price: $3.57
Change: -0.15 (3.91%)
Volume: 249.4 K
4:00PM ET 1/21/2022
 
 

Fortress Biotech Inc ( NASDAQ )

Price: $2.05
Change: -0.05 (2.38%)
Volume: 615.7 K
4:00PM ET 1/21/2022
 
 

Epizyme Inc ( NASDAQ )

Price: $2.07
Change: -0.12 (5.48%)
Volume: 954.0 K
4:00PM ET 1/21/2022
 
 

Co-Diagnostics Inc ( NASDAQ )

Price: $7.49
Change: -0.77 (9.32%)
Volume: 1.0 M
4:00PM ET 1/21/2022
 
 

Paratek Pharmaceuticals Inc ( NASDAQ )

Price: $3.99
Change: -0.10 (2.44%)
Volume: 398.5 K
4:00PM ET 1/21/2022
 

Read more news Recent News

Wedbush Trims Magenta Therapeutics' Price Target to $14 From $15, Keeps Outperform Rating
6:40AM ET 1/11/2022 MT Newswires

Magenta Therapeutics (MGTA) has an average rating of buy and price targets ranging from $6 to $20, according to analysts polled by Capital IQ. (MT...

Goldman Sachs Lifts Magenta Therapeutics to Buy From Neutral, Price Target to $8 From $7
5:15AM ET 1/06/2022 MT Newswires

Magenta Therapeutics (MGTA) has an average rating of buy and price targets ranging from $6 to $20, according to analysts polled by Capital IQ. (MT...

--B. Riley Lowers Magenta Therapeutics' PT to $13 from $19 on Lower Peak Sales for MGTA-145, Keeps Buy Rating
9:43AM ET 11/08/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Wedbush Adjusts Price Target for Magenta Therapeutics to $15 From $20, Maintains Outperform Rating
2:17PM ET 11/04/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionMagenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers patient preparation, stem cell collection, cell dose, and safe immune regeneration programs. Its platform include autologous and allogeneic transplant, and gene therapy. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 17, 2015 and is headquartered in Cambridge, MA. View company web site for more details
Address100 Technology Square
Cambridge, Massachusetts 02139
Phone+1.857.242.0170
Number of EmployeesN/A
Recent SEC Filing01/10/20228-K
President, Chief Executive Officer & DirectorJason Gardner
COO, CFO, Treasurer & Chief Accounting OfficerStephen Frank Mahoney
Chief Scientific Officer & Head-ResearchLisa M. Olson
Chief Technical OfficerDavid Nichols

Company Highlights

Price Open$3.72
Previous Close$3.71
52 Week Range$3.47 - 14.20
Market Capitalization$209.5 M
Shares Outstanding58.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.35
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-42.08%

Analyst Ratings as of 01/05/2022

Buy
6
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset